2024
An evaluation of treatment response and remission definitions in adult obsessive-compulsive disorder: A systematic review and individual-patient data meta-analysis
Ramakrishnan D, Farhat L, Vattimo E, Levine J, Johnson J, Artukoglu B, Landeros-Weisenberger A, Zangen A, Pelissolo A, de B Pereira C, Rück C, Costa D, Mataix-Cols D, Shannahoff-Khalsa D, Tolin D, Zarean E, Meyer E, Hawken E, Storch E, Andersson E, Miguel E, Maina G, Leckman J, Sarris J, March J, Diniz J, Kobak K, Mallet L, Vulink N, Amiaz R, Fernandes R, Shavitt R, Wilhelm S, Golshan S, Tezenas du Montcel S, Erzegovesi S, Baruah U, Greenberg W, Kobayashi Y, Bloch M. An evaluation of treatment response and remission definitions in adult obsessive-compulsive disorder: A systematic review and individual-patient data meta-analysis. Journal Of Psychiatric Research 2024, 173: 387-397. PMID: 38598877, DOI: 10.1016/j.jpsychires.2024.03.044.Peer-Reviewed Original ResearchConceptsYale-Brown Obsessive-Compulsive ScaleObsessive-compulsive disorderCGI-IRandomized-controlled trialsAdult obsessive-compulsive disorderClinical Global Impression ImprovementObsessive-Compulsive ScaleTreatment responseIndividual-patient data meta-analysisPosttreatment scoresEvaluation of treatment responseMeta-analysis of randomized-controlled trialsFirst-line therapyCGIIndividual participant dataMeta-analysisNovel treatment modalitiesExpert consensusIndividual participant data meta-analysisSystematic reviewDisordersData meta-analysisPosttreatmentRemission definitionsImpressive improvement
2014
Meta-analysis: hoarding symptoms associated with poor treatment outcome in obsessive–compulsive disorder
Bloch MH, Bartley CA, Zipperer L, Jakubovski E, Landeros-Weisenberger A, Pittenger C, Leckman JF. Meta-analysis: hoarding symptoms associated with poor treatment outcome in obsessive–compulsive disorder. Molecular Psychiatry 2014, 19: 1025-1030. PMID: 24912494, PMCID: PMC4169729, DOI: 10.1038/mp.2014.50.Peer-Reviewed Original ResearchConceptsObsessive-compulsive disorderTreatment responseOCD patientsOdds ratioFurther treatment researchCase-control studyPoor treatment outcomesDifferential treatment responseSymptoms of OCDPrimary outcomeTreatment modalitiesEligible studiesTreatment outcomesPatientsElectronic searchSymptomsTotal participantsBehavioral therapyOCD treatmentDisordersSymptom dimensionsTreatment researchDSM-5Hoarding symptomsTreatment
2009
Dimensional predictors of response to SRI pharmacotherapy in obsessive–compulsive disorder
Landeros-Weisenberger A, Bloch MH, Kelmendi B, Wegner R, Nudel J, Dombrowski P, Pittenger C, Krystal JH, Goodman WK, Leckman JF, Coric V. Dimensional predictors of response to SRI pharmacotherapy in obsessive–compulsive disorder. Journal Of Affective Disorders 2009, 121: 175-179. PMID: 19577308, PMCID: PMC3974618, DOI: 10.1016/j.jad.2009.06.010.Peer-Reviewed Original ResearchConceptsObsessive-compulsive disorderSRI responseSymptom dimensionsOpen-label continuation phaseClinical Global Improvement ScaleGlobal Improvement ScaleCentral serotonin systemInitial positive responseYale-Brown ObsessiveContinuation phaseMinor symptomsOrdinal logistic regressionClinical trialsSerotonin systemTreatment responseSame patientImprovement ScaleSRI treatmentPatientsSignificant associationLogistic regressionCompulsive ScaleOCD patientsOCD subjectsSymptoms
2007
Obsessive-Compulsive Disorder: An Open-Label Pilot Trial of Escitalopram
Galvão-de Almeida A, Quarantini LC, Góis CR, Santos-Jesus R, Miranda-Scippa AM, de Oliveira IR, da Silva Prado H, Leckman JF, Rosário MC. Obsessive-Compulsive Disorder: An Open-Label Pilot Trial of Escitalopram. CNS Spectrums 2007, 12: 519-524. PMID: 17603402, DOI: 10.1017/s1092852900021258.Peer-Reviewed Original ResearchConceptsObsessive-compulsive disorderYale-Brown ObsessiveTreatment responseOpen-label pilot trialSelective serotonin reuptake inhibitorsFourth Edition Axis IOpen-label studySerotonin reuptake inhibitorsOpen-label natureEdition Axis IStructured Clinical InterviewTotal Yale-Brown ObsessiveCompulsive Scale scoresReuptake inhibitorsDosage adjustmentNew medicationsPilot trialAxis IClinical InterviewPatientsScale scoreEscitalopramExperienced psychiatristsMental disordersUseful option
2006
A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder
Bloch MH, Landeros-Weisenberger A, Kelmendi B, Coric V, Bracken MB, Leckman JF. A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder. Molecular Psychiatry 2006, 11: 622-632. PMID: 16585942, DOI: 10.1038/sj.mp.4001823.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntipsychotic AgentsBasal Ganglia DiseasesBenzodiazepinesComorbidityDepressive DisorderDibenzothiazepinesDouble-Blind MethodDrug ResistanceDrug Therapy, CombinationHaloperidolHumansMiddle AgedObsessive-Compulsive DisorderOlanzapinePatient DropoutsQuetiapine FumarateRandomized Controlled Trials as TopicRisperidoneSelective Serotonin Reuptake InhibitorsTic DisordersTreatment OutcomeConceptsSerotonin reuptake inhibitorsAntipsychotic augmentationAbsolute risk differenceObsessive-compulsive disorderComorbid ticsOCD patientsTreatment responseSystematic reviewTreatment-refractory obsessive-compulsive disorderTreatment-refractory OCD patientsRefractory obsessive-compulsive disorderDouble-blind trialEfficacy of quetiapineTreatment-refractory OCDCochrane Central RegisterMeaningful treatment responseProportion of subjectsEfficacy of haloperidolRandomized control trialObsessive-compulsive disorder patientsSRI monotherapyAdequate trialCentral RegisterControlled TrialsReuptake inhibitors
2003
Tourette’s syndrome in children
Swain JE, Leckman JF. Tourette’s syndrome in children. Current Treatment Options In Neurology 2003, 5: 299-308. PMID: 12791197, DOI: 10.1007/s11940-003-0036-6.Peer-Reviewed Original ResearchTourette syndromeSide effectsComorbid conditionsPharmacologic agentsCourse of ticsLow-dose neurolepticsRealistic treatment expectationsAvailable pharmacologic agentsAttention deficit hyperactivity disorderBenefits of interventionsCommitted cliniciansDeficit hyperactivity disorderObsessive-compulsive disorderTreatment optionsSuccessful treatmentClinical trialsSomatic treatmentsTreatment responseSpecific symptomsEffective treatmentCommon treatmentTreatment expectationsTic severityTic controlNeurophysiologic basis
1994
Haloperidol Addition in Fluvoxamine-Refractory Obsessive-Compulsive Disorder: A Double-blind, Placebo-Controlled Study in Patients With and Without Tics
McDougle CJ, Goodman WK, Leckman JF, Lee NC, Heninger GR, Price LH. Haloperidol Addition in Fluvoxamine-Refractory Obsessive-Compulsive Disorder: A Double-blind, Placebo-Controlled Study in Patients With and Without Tics. JAMA Psychiatry 1994, 51: 302-308. PMID: 8161290, DOI: 10.1001/archpsyc.1994.03950040046006.Peer-Reviewed Original ResearchConceptsComorbid chronic tic disorderChronic tic disorderYale-Brown Obsessive Compulsive ScaleObsessive-compulsive disorderTic disordersFluvoxamine treatmentOCD patientsClinical Global Impression ScalePlacebo-treated groupDouble-blind fashionWeeks of treatmentGlobal Impression ScaleTreatment of patientsHaloperidol-treated groupEffective symptom reductionObsessive Compulsive ScaleNeuroleptic therapyBlood levelsImpression ScaleTreatment outcomesTreatment responseAdequate treatmentPatientsPlaceboSymptom reduction